NCT02713841View on ClinicalTrials.gov

Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

inhaled human insulin (INH)

recombinant human insulin administered with Adagio-01 inhaler device

DRUG

sc insulin lispro (LIS)

insulin lispro administered subcutaneously

Sponsors
All Listed Sponsors
lead

Dance Biopharm Inc.

INDUSTRY

NCT02713841 - Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes | Biotech Hunter | Biotech Hunter